Literature DB >> 19524655

The gastrointestinal stability of lipid nanocapsules.

E Roger1, F Lagarce, J-P Benoit.   

Abstract

The in vitro gastrointestinal stability of lipid nanocapsules (LNCs) was studied in different media. The size of LNCs was determined in simulated gastric and intestinal media. In updated fasted state simulated intestinal fluid (FaSSIF-V2) and updated fed state simulated intestinal fluid (FeSSIF-V2) media, the encapsulation ratio of paclitaxel-loaded LNCs was also measured. The size of LNCs was not modified after 3h in simulated gastric fluid and simulated intestinal fluid described by the United States Pharmacopeia, in FaSSIF, FaSSIF-V2, and in FeSSIF. Moreover, in the presence of pancreatin in FeSSIF-V2, a decreased above 30% of the loading of paclitaxel was observed. This was attributed to the presence of lipase in pancreatin that could interact with Lipoid (a mixture of phosphatidylcholine and phosphatidylethanolamine), present on the shell of LNC. As a conclusion, LNCs were stable on gastric medium and fasted state intestinal medium.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19524655     DOI: 10.1016/j.ijpharm.2009.05.069

Source DB:  PubMed          Journal:  Int J Pharm        ISSN: 0378-5173            Impact factor:   5.875


  16 in total

1.  G3.5 PAMAM dendrimers enhance transepithelial transport of SN38 while minimizing gastrointestinal toxicity.

Authors:  Deborah S Goldberg; Nirmalkumar Vijayalakshmi; Peter W Swaan; Hamidreza Ghandehari
Journal:  J Control Release       Date:  2010-11-27       Impact factor: 9.776

2.  Development of 2D and 3D mucus models and their interactions with mucus-penetrating paclitaxel-loaded lipid nanocapsules.

Authors:  Anne-Claire Groo; Kristina Mircheva; Jérôme Bejaud; Caroline Ailhas; Ivan Panaiotov; Patrick Saulnier; Tzvetanka Ivanova; Frederic Lagarce
Journal:  Pharm Res       Date:  2014-01-28       Impact factor: 4.200

3.  Paclitaxel Nano-Delivery Systems: A Comprehensive Review.

Authors:  Ping Ma; Russell J Mumper
Journal:  J Nanomed Nanotechnol       Date:  2013-02-18

4.  Efavirenz oral delivery via lipid nanocapsules: formulation, optimisation, and ex-vivo gut permeation study.

Authors:  Jaleh Varshosaz; Somayeh Taymouri; Ali Jahanian-Najafabadi; Arezoo Alizadeh
Journal:  IET Nanobiotechnol       Date:  2018-09       Impact factor: 1.847

5.  Oral fondaparinux: use of lipid nanocapsules as nanocarriers and in vivo pharmacokinetic study.

Authors:  Alyaa Ramadan; Frederic Lagarce; Anne Tessier-Marteau; Olivier Thomas; Pierre Legras; Laurent Macchi; Patrick Saulnier; Jean Pierre Benoit
Journal:  Int J Nanomedicine       Date:  2011-11-21

Review 6.  Developments in the use of nanocapsules in oncology.

Authors:  V Yurgel; T Collares; F Seixas
Journal:  Braz J Med Biol Res       Date:  2013-05-28       Impact factor: 2.590

7.  Praziquantel-lipid nanocapsules: an oral nanotherapeutic with potential Schistosoma mansoni tegumental targeting.

Authors:  Rokaya O Amara; Alyaa A Ramadan; Riham M El-Moslemany; Maha M Eissa; Mervat Z El-Azzouni; Labiba K El-Khordagui
Journal:  Int J Nanomedicine       Date:  2018-08-06

8.  Miltefosine Lipid Nanocapsules for Single Dose Oral Treatment of Schistosomiasis Mansoni: A Preclinical Study.

Authors:  Maha M Eissa; Riham M El-Moslemany; Alyaa A Ramadan; Eglal I Amer; Mervat Z El-Azzouni; Labiba K El-Khordagui
Journal:  PLoS One       Date:  2015-11-17       Impact factor: 3.240

9.  Fate of paclitaxel lipid nanocapsules in intestinal mucus in view of their oral delivery.

Authors:  Anne-Claire Groo; Patrick Saulnier; Jean-Christophe Gimel; Julien Gravier; Caroline Ailhas; Jean-Pierre Benoit; Frederic Lagarce
Journal:  Int J Nanomedicine       Date:  2013-11-07

10.  Plasmalogen enrichment in exosomes secreted by a nematode parasite versus those derived from its mouse host: implications for exosome stability and biology.

Authors:  Fabio Simbari; Jana McCaskill; Gillian Coakley; Marissa Millar; Rick M Maizels; Gemma Fabriás; Josefina Casas; Amy H Buck
Journal:  J Extracell Vesicles       Date:  2016-07-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.